recently became the first drugmaker to legally challenge the White House's Medicare drug price negotiation program - but the company's defense doesn't seem to have any legs, healthcare law expert Robin Feldman said in a recent interview.The pharmaceutical company filed a against the U.S. government on Tuesday, arguing that the program violates the Constitution's First and Fifth Amendments.
[
add
]
[
|
|
...
]